Hormonoterapia en cáncer de mama metastásico. Revisión de la Evidencia y Abordaje Terapéutico en el Instituto Nacional de Cancerología, Bogotá - Colombia

16.9% of breast cancer patients admitted to the Functional Unit for Breast and Soft Tissue Tumors of the National Cancer Institute of Colombia (INC) present with metastatic disease. The development of targeted therapies has radically modified the therapeutic approach in this group of patients. A literature search was conducted to select phase 3 randomized and controlled clinical trials, systematic reviews, and meta-analyses on systemic treatment for hormone receptor-positive (HR+) and HER2-receptor negative (HER2-) metastatic breast cancer. Filters were used to identify only articles published as of November 2020 and in the English language. Subsequently, the review of evidence was shared within the functional units for breast and soft tissue tumors and clinical oncology. Finally, an academic discussion was held to establish changes in the therapeutic approach of patients with luminal, HER2 negative, and metastatic breast cancer. In recent years, knowledge of the molecular biology of breast cancer has allowed the development of multiple targeted therapies (iCDK4/6, iPI3KCA, mTOR inhibitors), which, combined with hormonal therapy, improve the oncological outcomes of patients with metastatic disease (progression-free and overall survival).